b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31358432</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1938-0666</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>19</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical breast cancer</Title>\n                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>392-398</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(19)30307-6</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2019.05.019</ELocationID>\n            <Abstract>\n                <AbstractText>The landscape of therapeutic options for the treatment of hormone receptor (HR)-positive (HR<sup>+</sup>) HER2<sup>-</sup> breast cancer (BC) has been profoundly changed by the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into the metastatic setting. Currently all CDK4/6 inhibitors are approved only in the metastatic setting by Food and Drug Administration (FDA) and European Medicine Agency (EMA), whereas their role in the neoadjuvant setting is still at an investigational stage. Exploitation of novel agents such as CDK4/6 inhibitors to improve the efficacy of neoadjuvant endocrine therapy (ET) or to overcome de novo resistance to ET is an area of research under active evaluation. We present a review of the currently available data and ongoing clinical trials that are evaluating the role of CDK4/6 inhibitors in neoadjuvant therapy of HR<sup>+</sup> HER2<sup>-</sup> early BC, and also illustrate translational aspects, such as the potential biomarkers of response to these new therapeutic agents.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Rossi</LastName>\n                    <ForeName>Lorenzo</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy; Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland; Breast Unit of Southern Switzerland (CSSI), Lugano, Switzerland. Electronic address: lorenzo.rossi@eoc.ch.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>McCartney</LastName>\n                    <ForeName>Amelia</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Risi</LastName>\n                    <ForeName>Emanuela</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>De Santo</LastName>\n                    <ForeName>Irene</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Migliaccio</LastName>\n                    <ForeName>Ilenia</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Malorni</LastName>\n                    <ForeName>Luca</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Biganzoli</LastName>\n                    <ForeName>Laura</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Di Leo</LastName>\n                    <ForeName>Angelo</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>&quot;Sandro Pitigliani&quot; Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Clin Breast Cancer</MedlineTA>\n            <NlmUniqueID>100898731</NlmUniqueID>\n            <ISSNLinking>1526-8209</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Biomarkers</Keyword>\n            <Keyword MajorTopicYN="Y">CDK4/6 inhibitors</Keyword>\n            <Keyword MajorTopicYN="Y">Early breast cancer</Keyword>\n            <Keyword MajorTopicYN="Y">Neoadjuvant therapy</Keyword>\n            <Keyword MajorTopicYN="Y">Preoperative</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31358432</ArticleId>\n            <ArticleId IdType="pii">S1526-8209(19)30307-6</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.clbc.2019.05.019</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'